OSR Health, Inc. — Form 8-K
Filed August 7, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 72/100
What the filing says
OSR Health retracted claims that Nasdaq approved its Shareholder Loyalty CVR Program. Nasdaq provided only a preliminary, verbal technical indication on whether the program would trigger a mechanical stock-price adjustment—not endorsement. The August 14, 2026 record date remains unchanged, but the company now faces uncertainty on regulatory approval, with outcome pending SEC no-action request and Nasdaq's ultimate position.
Why this rating
Material reversal on regulatory signal for a micro-cap ($7.7M). CVR program legitimacy now heavily contested; execution risk acute.
See more from August 7, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.